The “cancer immunogram”
The DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.
Abstract
Visualizing the state of cancer–immune system interactions may spur personalized therapy
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“markers of response to cancer therapy have continued to evolve and now include factors well beyond established tumor-centric markers”
From The Influence of the Gut Microbiome on Cancer, Immunity, and Cancer Immunotherapy (2018) · cites this paper as Blank et al., 2016
Citations
Cites
Hallmarks of Cancer: The Next Generation
Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590
Immunity, Inflammation, and Cancer
Grivennikov, S. I., Greten, F. R., & Karin, M. (2010) · Cell · doi:10.1016/j.cell.2010.01.025 · Cited by 10,755
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
Le, D. T., Uram, J. N., Wang, H., Bartlett, B. R., Kemberling, H., Eyring, A. D., Skora, A. D., Luber, B. S., Azad, N. S., Laheru, D., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1500596 · Cited by 9,377
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
Larkin, J., Chiarion-Sileni, V., Gonzalez, R., Grob, J. J., Cowey, C. L., Lao, C. D., Schadendorf, D., Dummer, R., Smylie, M., Rutkowski, P., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504030 · Cited by 8,157
Self-citationMutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer
Rizvi, N. A., Hellmann, M. D., Snyder, A., Kvistborg, P., Makarov, V., Havel, J. J., Lee, W., Yuan, J., Wong, P., Ho, T. S., et al. (2015) · Science · doi:10.1126/science.aaa1348 · Cited by 7,802
Oncology meets immunology: the cancer-immunity cycle.
Chen, D. S., & Mellman, I. (2013) · Immunity · doi:10.1016/j.immuni.2013.07.012 · Cited by 6,929
PD-1 blockade induces responses by inhibiting adaptive immune resistance
Tumeh, P. C., Harview, C. L., Yearley, J. H., Shintaku, I. P., Taylor, E. J. M., Robert, L., Chmielowski, B., Spasic, M., Henry, G., Ciobanu, V., et al. (2014) · Nature · doi:10.1038/nature13954 · Cited by 6,609
The metabolism of tumors in the body
Warburg, O., Wind, F., & Negelein, E. (1927) · Journal of General Physiology · doi:10.1085/jgp.8.6.519 · Cited by 4,416
Wherry, E. J. (2011) · Nature Immunology · doi:10.1038/ni.2035 · Cited by 4,062
Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade
McGranahan, N., Furness, A. J. S., Rosenthal, R., Ramskov, S., Lyngaa, R., Saini, S. K., Jamal-Hanjani, M., Wilson, G. A., Birkbak, N. J., Hiley, C. T., et al. (2016) · Science · doi:10.1126/science.aaf1490 · Cited by 3,065
Cited by
Items 201–300 of 748
de Lima, V. A. B., Hansen, M., Spanggaard, I., Rohrberg, K. S., Hadrup, S. R., Lassen, U., & Svane, I. M. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.558248 · Cited by 65
Arellano, D. L., Juárez, P., Verdugo‐Meza, A., Almeida‐Luna, P. S., Corral‐Avila, J. A., Drescher, F., Olvera, F., Jiménez, S., Elzey, B. D., Guise, T. A., et al. (2020) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.4615 · Cited by 58
Immune Checkpoints in Cancers: From Signaling to the Clinic
Pisibon, C., Ouertani, A., Bertolotto, C., Ballotti, R., & Chéli, Y. (2021) · Cancers · doi:10.3390/cancers13184573 · Cited by 58
Novel Biomarkers for Personalized Cancer Immunotherapy
Shindo, Y., Hazama, S., Tsunedomi, R., Suzuki, N., & Nagano, H. (2019) · Cancers · doi:10.3390/cancers11091223 · Cited by 52
Uršič, K., Kos, Š., Kamenšek, U., Čemažar, M., Miceska, S., Markelc, B., Buček, S., Starešinič, B., Prevodnik, V. K., Heller, R. F., et al. (2021) · Journal of Controlled Release · doi:10.1016/j.jconrel.2021.03.009 · Cited by 60
Immune-checkpoint inhibitors in non-small cell lung cancer: A tool to improve patients’ selection
Banna, G. L., Passiglia, F., Colonese, F., Canova, S., Menis, J., Addeo, A., Russo, A. D., & Cortinovis, D. L. (2018) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2018.06.016 · Cited by 50
Zhang, H., Zhao, W., Li, X., & He, Y. (2021) · OncoTargets and Therapy · doi:10.2147/ott.s315998 · Cited by 55
Manufacturing Natural Killer Cells as Medicinal Products
Chabannon, C., Mfarrej, B. G., Guia, S., Ugolini, S., Devillier, R., Blaise, D., Vivier, É., & Calmels, B. (2016) · Frontiers in Immunology · doi:10.3389/fimmu.2016.00504 · Cited by 47
Emerging Biomarkers in Cutaneous Melanoma
Eisenstein, A. S., Gonzalez, E. C., Raghunathan, R., Xu, X., Wu, M., McLean, E. O., McGee, J. S., Ryu, B., & Alani, R. M. (2018) · Molecular Diagnosis & Therapy · doi:10.1007/s40291-018-0318-z · Cited by 52
Pembrolizumab for the treatment of non-small cell lung cancer
Muller, M., Schouten, R. D., de Gooijer, C. J., & Baas, P. (2017) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2017.1311791 · Cited by 51
Lybaert, L., Vermaelen, K. Y., Geest, B. G. D., & Nuhn, L. (2018) · Journal of Controlled Release · doi:10.1016/j.jconrel.2018.09.009 · Cited by 54
Immune Landscape in Tumor Microenvironment: Implications for Biomarker Development and Immunotherapy
Pérez‐Romero, K., Rodríguez, R. M. A., Amedei, A., Barceló‐Coblijn, G., & Lopez, D. H. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21155521 · Cited by 52
PD-1 and PD-L1 as emerging therapeutic targets in gastric cancer: current evidence
Tran, P. N., Sarkissian, S., Chao, J., & Klempner, S. J. (2017) · Gastrointestinal Cancer Targets and Therapy · doi:10.2147/gictt.s113525 · Cited by 46
Anti-PD-1 Therapy Leads to Near-Complete Remission in a Patient with Metastatic Basal Cell Carcinoma
Fischer, S., Ali, O. H., Jochum, W., Kluckert, T., Flatz, L., & Siano, M. (2018) · Oncology Research and Treatment · doi:10.1159/000487084 · Cited by 45
Current status and future perspectives of immunotherapy in bladder cancer treatment
Wu, Z., Liu, J., Dai, R., & Wu, S. (2020) · Science China Life Sciences · doi:10.1007/s11427-020-1768-y · Cited by 53
Thompson, K. J., Leon-Ferre, R. A., Sinnwell, J. P., Zahrieh, D., Suman, V. J., Metzger, O., Asad, S., Stover, D. G., Carey, L., Sikov, W. M., et al. (2022) · NAR Cancer · doi:10.1093/narcan/zcac018 · Cited by 48
The Tumor Immune Landscape and Architecture of Tertiary Lymphoid Structures in Urothelial Cancer
van Dijk, N., Gil-Jimenez, A., Siliņa, K., van Montfoort, M. L., Einerhand, S. M. H., Jonkman, L., Voskuilen, C. S., Peters, D. D. G. C., Sanders, J., Lubeck, Y., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.793964 · Cited by 55
Emery, A., Moore, S. E., Turner, J. E., & Campbell, J. P. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.788113 · Cited by 54
The effect of acute exercise on circulating immune cells in newly diagnosed breast cancer patients
Koivula, T., Lempiäinen, S., Rinne, P., Rannikko, J. H., Hollmén, M., Sundberg, C. J., Rundqvist, H., Minn, H. R. I., & HEINONEN, I. H. A. (2023) · Scientific Reports · doi:10.1038/s41598-023-33432-4 · Cited by 57
Queirolo, P., Dozin, B., Morabito, A., Banelli, B., Piccioli, P., Fava, C., Leo, C., Carosio, R., Laurent, S., Fontana, V., et al. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.00386 · Cited by 44
Recent Advances in Peptide-Based Approaches for Cancer Treatment
Conibear, A. C., Schmid, A., Kamalov, M., Becker, C. F. W., & Bello, C. (2017) · Current Medicinal Chemistry · doi:10.2174/0929867325666171123204851 · Cited by 45
Mitsuhashi, A., & Okuma, Y. (2018) · Clinical & Translational Oncology · doi:10.1007/s12094-017-1827-7 · Cited by 45
Immuno-oncology in GI tumours: Clinical evidence and emerging trials of PD-1/PD-L1 antagonists
Stein, A., Moehler, M. H., Trojan, J., Goekkurt, E., & Vogel, A. (2018) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2018.07.001 · Cited by 49
Metastatic Melanoma: Recent Therapeutic Progress and Future Perspectives
Malissen, N., & Grob, J. (2018) · Drugs · doi:10.1007/s40265-018-0945-z · Cited by 51
Zhao, C. N., & Rajan, A. (2019) · Mediastinum · doi:10.21037/med.2019.08.02 · Cited by 47
Ozaki, Y., Muto, S., Takagi, H., Watanabe, M., Inoue, T., Fukuhara, M., Yamaura, T., Okabe, N., Matsumura, Y., Hasegawa, T., et al. (2019) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-019-02446-1 · Cited by 43
Flesner, B. K., Wood, G. W., Gayheart-Walsten, P. A., Sonderegger, F. L., Henry, C. J., Tate, D. J., Axiak‐Bechtel, S. M., Donnelly, L. L., Johnson, G. C., Kim, D. Y., et al. (2020) · Journal of Veterinary Internal Medicine · doi:10.1111/jvim.15852 · Cited by 49
Li, S., Zhang, C., Pang, G., & Wang, P. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.603157 · Cited by 46
Recent Advances in Immunotherapy in Metastatic NSCLC
Bansal, P., Osman, D. I., Gan, G. N., Simon, G. R., & Boumber, Y. (2016) · Frontiers in Oncology · doi:10.3389/fonc.2016.00239 · Cited by 45
Ferrucci, P. F., Gandini, S., Cocorocchio, E., Pala, L., Baldini, F., Mosconi, M., Cappellini, G. C. A., Albertazzi, E., & Martinoli, C. (2017) · Oncotarget · doi:10.18632/oncotarget.19748 · Cited by 45
Yan, L., Wang, Z., Cui, C., Guan, X., Dong, B., Zhao, M., Wu, J., Tian, X., & Hao, C. (2019) · Cancer Science · doi:10.1111/cas.14161 · Cited by 49
Mandarano, M., Bellezza, G., Belladonna, M. L., Vannucci, J., Gili, A., Ferri, I., Lupi, C., Ludovini, V., Falabella, G., Metro, G., et al. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00839 · Cited by 45
GIS in Teacher Education - Facilitating GIS Applications in Secondary School Geography.
Johansson, T. (2003) · Cited by 68
Blake, Z., Marks, D. K., Gartrell, R. D., Hart, T. D., Horton, P., Cheng, S. K., Taback, B., Horst, B. A. J., & Saenger, Y. M. (2018) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-018-0338-6 · Cited by 43
Svatoň, M., Zemanová, M., Skřičková, J., Jakubíková, L., Kolek, V., Kultan, J., Koubková, L., Bejčková, A., Salajka, F., Hrnčiarik, M., et al. (2018) · Anticancer Research · doi:10.21873/anticanres.13048 · Cited by 41
Flies, A. S., Lyons, A. B., Corcoran, L. M., Papenfuss, A. T., Murphy, J. M., Knowles, G. W., Woods, G. M., & Hayball, J. D. (2016) · Frontiers in Immunology · doi:10.3389/fimmu.2016.00581 · Cited by 42
Integration of Nano drug-delivery System With Cancer Immunotherapy
Nakamura, T., & Harashima, H. (2017) · Therapeutic Delivery · doi:10.4155/tde-2017-0071 · Cited by 40
Yan, G., Wang, K., Shao, Z., Luo, L., Song, Z., Chen, J., Jin, R., Deng, X., Wang, H., Cao, Z., et al. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1713526115 · Cited by 42
Schouwenburg, M. G., Suijkerbuijk, K. P. M., Koornstra, R. H. T., Jochems, A., van Zeijl, M. C. T., van den Eertwegh, A. J. M., Haanen, J. B. A. G., Aarts, M. J. B., van Akkooi, A. C. J., van den Berkmortel, F. W. P. J., et al. (2019) · Cancers · doi:10.3390/cancers11121940 · Cited by 43
Randomized Controlled Immunotherapy Clinical Trials for GBM Challenged
Gool, S. V., Makalowski, J., Fiore, S., Sprenger, T., Prix, L., Schirrmacher, V., & Stuecker, W. (2020) · Cancers · doi:10.3390/cancers13010032 · Cited by 43
Lyu, Q., Lin, A., Cao, M., Xu, A., Luo, P., & Zhang, J. (2020) · Cancer Control · doi:10.1177/1073274820976665 · Cited by 40
Spatial immunoprofiling of the intratumoral and peritumoral tissue of renal cell carcinoma patients
Brück, O. E., Lee, M. H., Turkki, R., Uski, I., Penttilä, P., Paavolainen, L., Kovanen, P. E., Järvinen, P., Bono, P., Pellinen, T. S., et al. (2021) · Modern Pathology · doi:10.1038/s41379-021-00864-0 · Cited by 46
Therapy sculpts the complex interplay between cancer and the immune system during tumour evolution
Thol, K., Pawlik, P., & McGranahan, N. (2022) · Genome Medicine · doi:10.1186/s13073-022-01138-3 · Cited by 48
Xu, G., Sun, L., Li, Y., Xie, F., Zhou, X., Yang, H., Du, S., Xu, H., & Mao, Y. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00897 · Cited by 43
Peripheral blood immune cell-based biomarkers in anti-PD-1/PD-L1 therapy
Kim, K. H., Kim, C. G., & Shin, E. (2020) · Immune Network · doi:10.4110/in.2020.20.e8 · Cited by 39
Liu, W., Gui, C., Zhang, C., Liao, X., Xie, J., Liang, T., Liao, W., Song, L., & Zhang, X. (2021) · European Archives of Oto-Rhino-Laryngology · doi:10.1007/s00405-021-06879-2 · Cited by 38
Kamaraj, R., Ghosh, S., Das, S., Sen, S., Kumar, P. R., Majumdar, M., Dasgupta, R., Mukherjee, S., Das, S., Ghose, I., et al. (2024) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.4c00253 · Cited by 39
Shinohara, S., Takahashi, Y., Komuro, H., Matsui, T., Sugita, Y., Demachi‐Okamura, A., Muraoka, D., Takahara, H., Nakada, T., Sakakura, N., et al. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-003765 · Cited by 38
CTLA-4: As an Immunosuppressive Immune Checkpoint in Breast Cancer
Dehbokri, S. G., Alizadeh, N., Isazadeh, A., Baghbanzadeh, A., Abbaspour‐Ravasjani, S., Hajiasgharzadeh, K., & Baradaran, B. (2022) · Current Molecular Medicine · doi:10.2174/1566524022666220610094716 · Cited by 39
Krähenbühl, L., Goldinger, S. M., Mangana, J., Kerl, K., Chevolet, I., Brochez, L., Horak, C. E., Levesque, M. P., Dummer, R., & Cheng, P. F. (2018) · Neoplasia · doi:10.1016/j.neo.2017.12.002 · Cited by 39
Awada, G., Jansen, Y. J. L., Schwarze, J. K., Tijtgat, J., Hellinckx, L., Gondry, O., Vermeulen, S., Warren, S. E., Schats, K., van Dam, P., et al. (2021) · Cancers · doi:10.3390/cancers13020168 · Cited by 38
Thelen, M., Wennhold, K., Lehmann, J. M., Garcia-Marquez, M. A., Klein, S., Kochen, E., Lohneis, P., Lechner, A., Wagener‐Ryczek, S., Plum, P. S., et al. (2021) · npj Precision Oncology · doi:10.1038/s41698-021-00196-x · Cited by 38
Ribosome specialization in cancer: a spotlight on ribosomal proteins
Ramalho, S., Dopler, A., & Faller, W. J. (2024) · NAR Cancer · doi:10.1093/narcan/zcae029 · Cited by 43
P-stalk ribosomes act as master regulators of cytokine-mediated processes
Dopler, A., Alkan, F., Malka, Y., van der Kammen, R., Hoefakker, K., Taranto, D., Kocabay, N., Mimpen, I. L., Ramirez, C. F. A., Malzer, E., et al. (2024) · Cell · doi:10.1016/j.cell.2024.09.039 · Cited by 42
Sinha, A., Cha, B. G., Choi, Y., Nguyen, T. L., Yoo, P. J., Jeong, J. H., & Kim, J. (2017) · Chemistry of Materials · doi:10.1021/acs.chemmater.7b02197 · Cited by 37
Dissecting the Immune Landscape of Acute Myeloid Leukemia
Davidson-Moncada, J. K., Viboch, E., Church, S., Warren, S. E., & Rutella, S. (2018) · Biomedicines · doi:10.3390/biomedicines6040110 · Cited by 38
Advances in theranostic biomarkers for tumor immunotherapy
Bellesœur, A., Torossian, N., Amigorena, S., & Romano, E. (2020) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2020.02.005 · Cited by 35
Camy, F., Karpathiou, G., Dumollard, J. M., Magné, N., Perrot, J., Vassal, F., Picot, T., Mobarki, M., Forest, F., Casteillo, F., et al. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-000597 · Cited by 35
Mukherjee, G., Bag, S., Chakraborty, P., Dey, D., Roy, S., Jain, P. V., Roy, P., Soong, R., Majumder, P. P., & Dutt, S. (2020) · PLoS ONE · doi:10.1371/journal.pone.0242058 · Cited by 38
Epigenetic Regulation of Immunotherapy Response in Triple-Negative Breast Cancer
Llinàs‐Arias, P., Íñiguez-Muñoz, S., McCann, K. E., Voorwerk, L., Orozco, J. I. J., Ensenyat-Méndez, M., Sesé, B., DiNome, M. L., & Marzese, D. M. (2021) · Cancers · doi:10.3390/cancers13164139 · Cited by 37
Glycans Pave the Way for Immunotherapy in Triple-Negative Breast Cancer
Salatino, M., Girotti, M. R., & Rabinovich, G. A. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.01.015 · Cited by 34
Find the Flame: Predictive Biomarkers for Immunotherapy in Melanoma
Garutti, M., Bonin, S., Buriolla, S., Bertoli, E., Pizzichetta, M. A., Zalaudek, I., & Puglisi, F. (2021) · Cancers · doi:10.3390/cancers13081819 · Cited by 38
Roussel, H., Guillebon, É. D., Biard, L., Mandavit, M., Gibault, L., Fabre, E., Antoine, M., Hofman, P. M., Beau‐Faller, M., Blons, H., et al. (2017) · OncoImmunology · doi:10.1080/2162402x.2017.1286437 · Cited by 32
Brogden, K. A., Parashar, D., Hallier, A. R., Braun, T. A., Fang, Q., Rizvi, N. A., Bossler, A., Milhem, M. M., Chan, T. A.-T., Abbasi, T., et al. (2018) · BMC Cancer · doi:10.1186/s12885-018-4134-y · Cited by 36
Jones, N., Xiu, J., Rocconi, R. P., Herzog, T. J., & Winer, I. S. (2019) · Gynecologic Oncology · doi:10.1016/j.ygyno.2019.11.035 · Cited by 44
Contribution of Macrophages and T Cells in Skeletal Metastasis
Mendoza‐Reinoso, V., McCauley, L. K., & Fournier, P. G. J. (2020) · Cancers · doi:10.3390/cancers12041014 · Cited by 37
Takkenkamp, T. J., Jalving, M., Hoogwater, F. J. H., & Walenkamp, A. (2020) · Endocrine Related Cancer · doi:10.1530/erc-20-0113 · Cited by 37
Epigenetic Control of Cdkn2a.Arf Protects Tumor-Infiltrating Lymphocytes from Metabolic Exhaustion
Koss, B. S., Shields, B. D., Taylor, E. M., Storey, A. J., Byrum, S. D., Gies, A. J., Washam, C. L., Choudhury, S. R., Ahn, J. H., Uryu, H., et al. (2020) · Cancer Research · doi:10.1158/0008-5472.can-20-0524 · Cited by 37
Immunotherapy for the treatment of colorectal cancer
Lumish, M. A., & Cercek, A. (2021) · Journal of Surgical Oncology · doi:10.1002/jso.26357 · Cited by 38
Artificial intelligence for solid tumour diagnosis in digital pathology
Klein, C., Zeng, Q., Arbaretaz, F., Devêvre, E., Caldéraro, J., Loménie, N., & Maiuri, M. C. (2021) · British Journal of Pharmacology · doi:10.1111/bph.15633 · Cited by 41
Combined nano cancer immunotherapy based on immune status in a tumor microenvironment
Nakamura, T., Kawakami, K., Nomura, M., Sato, Y., Hyodo, M., Hatakeyama, H., Hayakawa, Y., & Harashima, H. (2022) · Journal of Controlled Release · doi:10.1016/j.jconrel.2022.03.026 · Cited by 34
Grizzi, G., Caccese, M., Γκουντάκος, Α., Carbognin, L., Tortora, G., Bria, E., & Pilotto, S. (2017) · Expert Review of Molecular Diagnostics · doi:10.1080/14737159.2017.1393333 · Cited by 34
Koemans, W. J., Chalabi, M., van Sandick, J. W., van Dieren, J. M., & Kodach, L. L. (2018) · Cancer Letters · doi:10.1016/j.canlet.2018.11.001 · Cited by 34
Rasmusson, A., Zilenaite-Petrulaitiene, D., Nestarenkaitė, A., Augulis, R., Laurinavičienė, A., Ostapenko, V., Poškus, T., & Laurinavičius, A. (2020) · American Journal Of Pathology · doi:10.1016/j.ajpath.2020.01.018 · Cited by 33
Immunotherapy for Metastatic Non-Small Cell Lung Cancer: Therapeutic Advances and Biomarkers
Russano, M., Cava, G. L., Cortellini, A., Citarella, F., Galletti, A., Fazio, G. R. D., Santo, V., Brunetti, L., Vendittelli, A., Fioroni, I., et al. (2023) · Current Oncology · doi:10.3390/curroncol30020181 · Cited by 35
Tumor Glycosylation: A Main Player in the Modulation of Immune Responses
Rodríguez, E. (2025) · European Journal of Immunology · doi:10.1002/eji.202451318 · Cited by 37
New Frontiers for Molecular Pathology
Domagala-Kulawik, J. J. (2019) · Frontiers in Medicine · doi:10.3389/fmed.2019.00284 · Cited by 36
Vγ9Vδ2 T Cells: Can We Re-Purpose a Potent Anti-Infection Mechanism for Cancer Therapy?
Künkele, K., Wesch, D., Oberg, H., Aichinger, M., Supper, V., & Baumann, C. (2020) · Cells · doi:10.3390/cells9040829 · Cited by 34
Ortega-Franco, A., Ackermann, C. J., Paz-Ares, L. G., & Califano, R. (2021) · ESMO Open · doi:10.1016/j.esmoop.2020.100003 · Cited by 36
Integrative Genomic Profiling Uncovers Therapeutic Targets of Acral Melanoma in Asian Populations
Shi, Q., Liu, L., Chen, J., Zhang, W., Guo, W., Wang, X., Wang, H., Guo, S., Yue, Q., Ma, J., et al. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-3344 · Cited by 33
Valero, C., Golkaram, M., Vos, J. L., Xu, B., Fitzgerald, C. W. R., Lee, M., Kaplan, S., Han, C. Y., Pei, X., Sarkar, R. R., et al. (2023) · Journal of Clinical Investigation · doi:10.1172/jci169823 · Cited by 34
Lee, S., Eo, W. K., Jeon, H., Park, S., & Chae, J. (2017) · Journal of Cancer · doi:10.7150/jca.20866 · Cited by 35
Phenotype molding of T cells in colorectal cancer by single‐cell analysis
Di, J., Liu, M., Fan, Y., Gao, P., Wang, Z., Jiang, B., & Su, X. (2020) · International Journal of Cancer · doi:10.1002/ijc.32856 · Cited by 37
Hoefsmit, E. P., Rozeman, E. A., Haanen, J. B. A. G., & Blank, C. U. (2019) · ESMO Open · doi:10.1136/esmoopen-2018-000472 · Cited by 29
Tumor-Targeted Nonablative Radiation Promotes Solid Tumor CAR T-cell Therapy Efficacy
Quach, H. T., Skovgard, M. S., Villena‐Vargas, J., Bellis, R. Y., Chintala, N. K., Amador-Molina, A., Bai, Y., Banerjee, S., Saini, J. K., Xiong, Y., et al. (2023) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-22-0840 · Cited by 35
Ahmed, J., Das, B., Shin, S. J., & Chen, A. P. (2023) · Cancers · doi:10.3390/cancers15245841 · Cited by 44
Tumor mutational burden in colorectal cancer: Implications for treatment
Marques, A., Cavaco, P., Torre, C., Sepodes, B. M. N., & Rocha, J. P. (2024) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2024.104342 · Cited by 38
Mechanisms of Resistance to Anti-PD-1 Immunotherapy in Melanoma and Strategies to Overcome It
Zielińska, M. K., Ciążyńska, M. A., Sulejczak, D., Rutkowski, P. L., & Czarnecka, A. M. (2025) · Biomolecules · doi:10.3390/biom15020269 · Cited by 36
Califano, R., Lal, R., Lewanski, C. R., Nicolson, M. C., Ottensmeier, C. H. H., Popat, S., Hodgson, M. J., & Postmus, P. E. (2018) · Future Oncology · doi:10.2217/fon-2018-0330 · Cited by 37
Stochastic modeling of tumor progression and immune evasion
George, J. T., & Levine, H. (2018) · Journal of Theoretical Biology · doi:10.1016/j.jtbi.2018.09.012 · Cited by 30
A High-Dimensional Window into the Micro-Environment of Triple Negative Breast Cancer
Nederlof, I., Horlings, H. M., Curtis, C. N., & Kok, M. (2021) · Cancers · doi:10.3390/cancers13020316 · Cited by 34
Adoptive tumor infiltrating lymphocytes cell therapy for cervical cancer
Zhu, Y., Zhou, J., Zhu, L., Hu, W., Liu, B., & Xie, L. (2022) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2022.2060019 · Cited by 31
Tan, L. Y., Martini, C., Fridlender, Z. G., Bonder, C. S., Brown, M. P., & Ebert, L. M. (2017) · Clinical & Translational Immunology · doi:10.1038/cti.2017.7 · Cited by 34
Constitutive and acquired mechanisms of resistance to immune checkpoint blockade in human cancer
Bellone, M., & Elia, A. R. (2017) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2017.06.002 · Cited by 35
Defining the Tumor Microenvironment of Penile Cancer by Means of the Cancer Immunogram
de Vries, H. M., Ottenhof, S. R., Horenblas, S., van der Heijden, M. S., & Jordanova, E. S. (2019) · European Urology Focus · doi:10.1016/j.euf.2019.02.019 · Cited by 32
Grob, J., Garbe, C., Ascierto, P. A., Larkin, J., Dummer, R., & Schadendorf, D. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30596-5 · Cited by 30
Voluntary wheel running can lead to modulation of immune checkpoint molecule expression
Bay, M. L., Unterrainer, N., Stagaard, R., Pedersen, K. S., Schauer, T., Staffeldt, M. M., Christensen, J. F., Højman, P., Pedersen, B. K., & Gehl, J. (2020) · Acta Oncologica · doi:10.1080/0284186x.2020.1817550 · Cited by 33
Bugs as drugs: The role of microbiome in cancer focusing on immunotherapeutics
Araujo, D. V., Watson, G. A., Oliva, M., Heirali, A., Coburn, B., Spreafico, A., & Siu, L. L. (2021) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2020.102125 · Cited by 29
Chen, Z., Wu, Y., Yao, Z., Su, J., Wang, Z., Xia, H., & Liu, S. (2022) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.2c12990 · Cited by 29
Immunotherapy for brain metastases and primary brain tumors
Giacomo, A. M. D., Mair, M. J., Ceccarelli, M., Anichini, A., Ibrahim, R. A., Weller, M., Lahn, M., Eggermont, A. M. M., Fox, B. A., & Maio, M. (2022) · European Journal of Cancer · doi:10.1016/j.ejca.2022.11.012 · Cited by 39
Metadata
- Authors
- Blank, C. U., Haanen, J. B., Ribas, A., & Schumacher, T. N.
- Affiliations
- The Netherlands Cancer Institute (NL)
- University of California, Los Angeles (US)
- Venue
- Science
- Published
- 2016-05-06
- Volume
- 352
- Issue
- 6286
- Pages
- 658-660
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- OpenAlex
- W2346108121
- Cited by
- 748
- References
- 36
- Citations by year
- 2026: 23 · 2025: 37 · 2024: 54 · 2023: 61 · 2022: 66 · 2021: 92 · 2020: 113 · 2019: 78 · 2018: 104 · 2017: 94 · 2016: 23
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Science (publishedVersion)
- PubMed (publishedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Keywords
- tumor-immune interactions, tumor immune microenvironment, immune checkpoint inhibitors, precision oncology, immune profiling
- MeSH terms
- Animals, Humans, Immunotherapy, Macrophages, Neoplasms, T-Lymphocytes, Biomarkers, Tumor, Lymphocytes, Tumor-Infiltrating, Tumor Escape, Mice, Precision Medicine, Microbiota
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.